[go: up one dir, main page]

WO2003012104A1 - Nouvelle proteine de recepteurs couples aux proteines g et adn de celle-ci - Google Patents

Nouvelle proteine de recepteurs couples aux proteines g et adn de celle-ci Download PDF

Info

Publication number
WO2003012104A1
WO2003012104A1 PCT/JP2002/007773 JP0207773W WO03012104A1 WO 2003012104 A1 WO2003012104 A1 WO 2003012104A1 JP 0207773 W JP0207773 W JP 0207773W WO 03012104 A1 WO03012104 A1 WO 03012104A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
novel
dna
coupled receptor
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007773
Other languages
English (en)
Japanese (ja)
Inventor
Shuji Sato
Yasushi Shintani
Nobuyuki Miyajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of WO2003012104A1 publication Critical patent/WO2003012104A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une nouvelle protéine utile dans le criblage d'un agoniste/antagoniste, etc.. Elle concerne plus spécifiquement une protéine d'origine humaine ou son sel ; l'ADN codant pour cette protéine ; un procédé permettant de déterminer un ligand de cette protéine ; un procédé/une trousse pour obtenir par criblage un composé capable de modifier les propriétés de liaison du ligand à la protéine ; les composés obtenus par ce criblage ou leurs sels, etc..
PCT/JP2002/007773 2001-08-01 2002-07-31 Nouvelle proteine de recepteurs couples aux proteines g et adn de celle-ci Ceased WO2003012104A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-234295 2001-08-01
JP2001234295A JP2003047472A (ja) 2001-08-01 2001-08-01 新規ｇタンパク質共役型レセプタータンパク質およびそのｄｎａ

Publications (1)

Publication Number Publication Date
WO2003012104A1 true WO2003012104A1 (fr) 2003-02-13

Family

ID=19065927

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007773 Ceased WO2003012104A1 (fr) 2001-08-01 2002-07-31 Nouvelle proteine de recepteurs couples aux proteines g et adn de celle-ci

Country Status (2)

Country Link
JP (1) JP2003047472A (fr)
WO (1) WO2003012104A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972800B2 (en) 2003-04-25 2011-07-05 Takeda Pharmaceutical Company Limited Screening method for binding property or signal transduction alterations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4542810B2 (ja) * 2003-04-25 2010-09-15 武田薬品工業株式会社 新規スクリーニング方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887407A2 (fr) * 1997-06-11 1998-12-30 Smithkline Beecham Corporation Clone HAPO167 de ADNc codant pour un nouveau récepteur 7-transmembrane humain
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887407A2 (fr) * 1997-06-11 1998-12-30 Smithkline Beecham Corporation Clone HAPO167 de ADNc codant pour un nouveau récepteur 7-transmembrane humain
WO2001009328A1 (fr) * 1999-08-03 2001-02-08 Millennium Pharmaceuticals, Inc. Nouvelle molecule 15571 de type gpcr de la famille secretine et utilisations de cette derniere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAGASE T. ET AL.: "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro", DNA RES., vol. 7, no. 2, 28 April 2000 (2000-04-28), pages 143 - 150, XP008010899 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972800B2 (en) 2003-04-25 2011-07-05 Takeda Pharmaceutical Company Limited Screening method for binding property or signal transduction alterations

Also Published As

Publication number Publication date
JP2003047472A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
WO2002084286A1 (fr) Procede de criblage
PT2784084T (pt) Anticorpos antagonistas contra polipéptidos heterólogos il-17a/f
PL376993A1 (pl) Pochodne fenylo- lub heteroarylo-aminoalkanów jako antagoniści receptora IP
WO2001077172A3 (fr) Recepteurs connus couples a la proteine g non endogenes a activation constitutive
WO2006131659A3 (fr) Compositions de liant rapide pour pieces et ouvrages en beton contenant un sel de calcium
MXPA03008944A (es) Inhibidores de la procolageno c proteinasa basados en acidos 3-heterociclilpropanohidroxamicos.
WO2002044368A1 (fr) Nouvelles proteines du recepteur couple a la proteine g et leurs adn
WO2003012104A1 (fr) Nouvelle proteine de recepteurs couples aux proteines g et adn de celle-ci
AU2003242106A1 (en) Detection kit, assay plate to be used therein, detection method, evaluation method, polyclonal antibody of frog vitellogenin and procss for producing the same
EP1255109A4 (fr) Procede de criblage
WO2002004624A9 (fr) Nouvelle proteine receptrice couplee a la proteine g et adn destine a celle-ci
WO2002060948A1 (fr) Nouvelle proteine recepteur couplee a une proteine g et adn correspondant
ATE497947T1 (de) Neue 1,3-disubstituierte azetidinderivate zur verwendung als liganden des 5ht2a-rezeptors
WO2003082320A1 (fr) Nouveau procede de criblage
WO2002061075A1 (fr) Proteine de recepteur couple aux proteines g et adn correspondant
DE602004030899D1 (de) Neues screening-verfahren
WO2002083938A3 (fr) Procedes de criblage pour l'identification de ligands
AU2003242311A1 (en) Composition for aldehyde detection
GB0328892D0 (en) Positive signal assay for analytes
AU2002220526A1 (en) Method of identifying compounds capable of acting as agonists or antagonists of g-protein coupled receptors
WO2003008445A1 (fr) Nouvelle proteine receptrice couplee a la proteine g, et adn codant pour elle
WO2006018259A3 (fr) Procede de detection d'agoniste ou d'antagoniste transporteur de carnitine et utilisations
AU2002220526A (en) Method of identifying compounds capable of acting as agonists or antagonists of g-protein coupled receptors
WO2002061083A1 (fr) Nouvelle proteine de recepteur couple aux proteines g et son adn
WO2004027427A8 (fr) Analyse de ligands fprl-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase